menu
    • menu
    [{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Albendazole","moa":"||Tubulin","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Albendazole","moa":"||Tubulin","graph1":"Gastroenterology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Medicines Development for Global Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Moxidectin","moa":"||Gamma-aminobutyric acid receptor (GAR)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Medicines Development for Global Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medicines Development for Global Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Medicines Development for Global Health \/ Inapplicable"},{"orgOrder":0,"company":"Barcelona Institute for Global Health","sponsor":"Leiden University Medical Center | Bahir Dar University | Centro de Investigacao em Saude de Manhica | London School of Hygiene & Tropical Medicine | Kenya Medical Research Institute | Laboratorios Liconsa | Universidad de Le\u00f3n | European & Developing Cou","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Albendazole","moa":"||Tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Barcelona Institute for Global Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Barcelona Institute for Global Health \/ Leiden University Medical Center | Bahir Dar University | Centro de Investigacao em Saude de Manhica | London School of Hygiene & Tropical Medicine | Kenya Medical Research Institute | Laboratorios Liconsa | Universidad de Le\u00f3n | European & Developing Cou","highestDevelopmentStatusID":"9","companyTruncated":"Barcelona Institute for Global Health \/ Leiden University Medical Center | Bahir Dar University | Centro de Investigacao em Saude de Manhica | London School of Hygiene & Tropical Medicine | Kenya Medical Research Institute | Laboratorios Liconsa | Universidad de Le\u00f3n | European & Developing Cou"}]

    Find Clinical Drug Pipeline Developments & Deals for ALBENDAZOLE [EP MONOGRAPH]

    Menu

    ALBENDAZOLE [EP MONOGRAPH]

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Dr. Reddy's Laboratories

                            India
                            CPhI Korea
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

                            Lead Product(s) : Albendazole,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dr. Reddy's Laboratories Announces the Launch of Albendazole Tablets, USP in the U.S. Market

                            Details : Albendazole Tablets, USP, a therapeutic equivalent generic version of Albenza Tablets, 200 mg, approved by the U.S. Food and Drug Administration. Dr. Reddy’s Albendazole Tablets, USP are available in 200 mg tablets in bottle count sizes of two.

                            Product Name : Albendazole-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 29, 2021

                            Lead Product(s) : Albendazole,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Dr Reddy Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            GSK

                            United Kingdom arrow
                            EPSC
                            Not Confirmed

                            GSK

                            United Kingdom arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Albendazole,Inapplicable

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study Between Two Albendazole 400 mg Tablets in Healthy Adult Participants Under Fed Conditions

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 11, 2024

                            Lead Product(s) : Albendazole,Inapplicable

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Barcelona Institute for Global Health

                            Country arrow
                            EPSC
                            Not Confirmed

                            Barcelona Institute for Global Health

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Albendazole,Ivermectin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Leiden University Medical Center | Bahir Dar University | Centro de Investigacao em Saude de Manhica | London School of Hygiene & Tropical Medicine | Kenya Medical Research Institute | Laboratorios Liconsa | Universidad de León | European & Developing Cou

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of Effectiveness of ALBENDAZOLIVERMECTIN Coformulation vs ALBENDAZOLE for Treatment of Intestinal W...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 18, 2021

                            Lead Product(s) : Albendazole,Ivermectin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Leiden University Medical Center | Bahir Dar University | Centro de Investigacao em Saude de Manhica | London School of Hygiene & Tropical Medicine | Kenya Medical Research Institute | Laboratorios Liconsa | Universidad de León | European & Developing Cou

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Medicines Development for Global Health

                            Australia arrow
                            EPSC
                            Not Confirmed

                            Medicines Development for Global Health

                            Australia arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Moxidectin,Albendazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 17, 2020

                            Lead Product(s) : Moxidectin,Albendazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            London School of Hygiene & Tropical Medicine

                            Country arrow
                            EPSC
                            Not Confirmed

                            London School of Hygiene & Tropical Medicine

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Albendazole,Ivermectin,Azithromycin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Armauer Hansen Research Institute, Ethiopia | Federal Minstry of Health of Ethiopia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cluster RCT of Co-administration Azithromycin, Albendazole & Ivermectin

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 27, 2018

                            Lead Product(s) : Albendazole,Ivermectin,Azithromycin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Armauer Hansen Research Institute, Ethiopia | Federal Minstry of Health of Ethiopia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Institut Pasteur

                            Country arrow
                            EPSC
                            Not Confirmed

                            Institut Pasteur

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Albendazole,Fortified Blend Flour,Azithromycin,Inulin,Fructo-Oligosaccharide

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase III

                            Sponsor : Action Contre la Faim | Centre de Recherches Médicales et Sanitaires CERMES Niger | Institut Pasteur de Madagascar | Institut Pasteur de Bangui | Institut Pasteur de Dakar

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparing Several Strategies to Manage Moderate Acute Malnutrition Among Children From 6 to 24 Months Old

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 22, 2018

                            Lead Product(s) : Albendazole,Fortified Blend Flour,Azithromycin,Inulin,Fructo-Oligosaccharide

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase III

                            Sponsor : Action Contre la Faim | Centre de Recherches Médicales et Sanitaires CERMES Niger | Institut Pasteur de Madagascar | Institut Pasteur de Bangui | Institut Pasteur de Dakar

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Washington University School of Medicine

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Washington University School of Medicine

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IDA,Diethylcarbamazine,Albendazole,Ivermectin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : The Task Force for Global Health | Murdoch Childrens Research Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Fiji Integrated Therapy (FIT) - Triple Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminth...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 06, 2017

                            Lead Product(s) : IDA,Diethylcarbamazine,Albendazole,Ivermectin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : The Task Force for Global Health | Murdoch Childrens Research Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Noguchi Memorial Institute for Medical Research

                            Country arrow
                            EPSC
                            Not Confirmed

                            Noguchi Memorial Institute for Medical Research

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ivermectin,Albendazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Ghana Health Service

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Twice Yearly Treatment for the Control of LF

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 30, 2017

                            Lead Product(s) : Ivermectin,Albendazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Ghana Health Service

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Centre d'Appui à la lutte contre la Maladie

                            Country arrow
                            EPSC
                            Not Confirmed

                            Centre d'Appui à la lutte contre la Maladie

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Albendazole,Ivermectin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Malaria Research and Training Center, Bamako, Mali | World Health Organization

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Impact of Albendazole -Ivermectin on Wuchereria Bancrofti in Mali

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 27, 2016

                            Lead Product(s) : Albendazole,Ivermectin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Malaria Research and Training Center, Bamako, Mali | World Health Organization

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Oxford University Clinical Research Unit, Vietnam

                            Country arrow
                            EPSC
                            Not Confirmed

                            Oxford University Clinical Research Unit, Vietnam

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Albendazole,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam | Ho Chi Minh Preventive Medicine Centre, Vietnam | Princeton University | Cu Chi Health Department

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Impact of Anthelmintic Treatment on the Incidence of Diarrheal Disease in Vietnamese School Children

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 05, 2015

                            Lead Product(s) : Albendazole,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam | Ho Chi Minh Preventive Medicine Centre, Vietnam | Princeton University | Cu Chi Health Department

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth